Table 1 Clinical, haematological and cytogenetic features of adult primary myelodysplastic syndrome (MDS)

Table 1A: Clinical and haematological features

Characteristic

N (%)

No. of patients with MDS

988

Median age (range)

53 years (18–86)

No. of patients ≥ 21 years (%)

899 (96)

Median age of patients ≥ 21 years (range)

53 years (21–86)

No. of patients ≥ 40 years (%)

696 (74)

Median age of patients ≥ 40 years (range)

58 years (40–86)

Males / females (M: F ratio)

607/329 (1.8:1)

Blood counts

Hemoglobin, g/dL, n = 929

<10

787(84.7)

≥10

142(15.3)

Platelet count, ×10⁹/L, n = 929

<100,000

619(66.6)

≥100,000

310(33.4)

Absolute neutrophil count (ANC), ×10⁹/L, n = 919

<0.8

610(66.4)

≥0.8

309(33.6)

Single cytopenia

237(25.5)

Anemia

165(17.8)

Thrombocytopenia

51(5.5)

Leucopenia

21(2.3)

Bicytopenia

311(33.5)

Anemia & thrombocytopenia

165(18)

Anemia & leucopenia

98(10.7)

Thrombocytopenia & leucopenia

48(14.1)

Pancytopenia

346(37.6)

Table 1B. Overview of cytogenetic findings

Characteristic

N (%)

Successful cytogenetic analyses

936 (94.7)

Normal karyotypes

421(44.9)

Clonal cytogenetic abnormalities

515(55)

Numerical abnormalities only

131 (25.4)

Structural abnormalities only

201(39)

Numerical and structural abnormalities

183 (35.5)

Cytogenetic abnormalities

Single abnormality

279(29.8)

Two abnormalities

70(7.5)

≥2 independent non-complex clones

25(2.7)

Complex KT, ≥3 abnormalities

141(15)

Complex KT with 3 abnormalities

36(3.8)

Complex KT with >3 abnormalities

105(11.2)

Table 1C. Cytogenetic prognosis and clinical risk groups

Cytogenetic prognosis groups (as per CCSS and IPSS-R)

N (%)

Very good prognosis

19(2)

Good prognosis, all / abnormal KT only

520(55.6)/99(10.6)

Intermediate prognosis

152(16.2)

Poor prognosis

140(15)

Very poor prognosis

105(11.2)

Clinical (IPSS-R) risk groups, n = 842

N (%)

Very low risk

33(3.9)

Low risk

260(30.9)

Intermediate risk

204(24.2)

High risk

177(21)

Very high risk

168(20)